AOBiome Therapeutics has reported that its Phase IIb clinical trial of B244 for pruritus (itch) and appearance in atopic dermatitis (eczema) met all its primary and secondary endpoints.
CAMBRIDGE, Mass., Nov. 16, 2021 /PRNewswire/ -- AOBiome Therapeutics, a leading clinical-stage biotechnology company focusing on inflammation, announced completion of enrollment in its Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis. This trial is based on previous positive clinical trial results related to the investigation of its lead product candidate, B244, a live topical biotherapeutic, in patients with atopic dermatitis (eczema) in a 122 subject Phase 2a clinical trial in adults as well as a 28 subject Phase 1b clinical trial in pediatric patients with 28 patients. The company believes that its current 547 subject study is the largest Clinical Trial ever run using a live topical biotherapeutic by a wide margin.